Skyepharma kicks off bond buyback after £112m capital raise
Pharmaceutical firm Skyepharma has launched a buyback of its 6.5% 2024 bonds after completing a £112m capital raise.
Unlock this article.
The content you are trying to view is exclusive to our subscribers.
To unlock this article:
- ✔ 4,000 annual insights
- ✔ 700+ notes and long-form analyses
- ✔ 4 capital markets databases
- ✔ Daily newsletters across markets and asset classes
- ✔ 2 weekly podcasts